Nubeqa (Darolutamide)

Darolutamide, the active ingredient in Nubeqa, is a non‑steroidal anti‑androgen presented as a tablet for oral use. It treats non‑metastatic castration‑resistant prostate cancer in men who have progressed despite androgen‑deprivation therapy.

GNH USA supplies Nubeqa as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

Nubeqa is indicated for prostate‑cancer treatment within the androgen‑receptor signalling pathway. - Non‑metastatic castration‑resistant prostate cancer (nmCRPC): delays metastasis and prolongs overall survival. - High‑risk localized prostate cancer (in combination with radiation therapy): improves biochemical recurrence‑free survival. - Metastatic castration‑resistant prostate cancer (mCRPC) after prior hormonal therapy: provides an additional line of hormonal control.

Adverse reactions reported with darolutamide include both frequent and rare events.

Common Side Effects: - Fatigue: mild to moderate tiredness reported by many patients. - Rash: skin erythema or maculopapular eruptions. - Hypertension: increase in blood pressure requiring monitoring. - Diarrhoea: loose stools, often transient. - Nausea: occasional feeling of queasiness. - Elevated liver enzymes: mild transaminase rise.

Serious or Rare Side Effects: - Seizures: infrequent but documented neurological events. - Severe hepatic injury: marked elevation of liver enzymes or hepatitis. - Cardiovascular events: myocardial infarction or stroke. - Pulmonary embolism: rare clotting complication. - Anaphylaxis: severe allergic reaction. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating darolutamide, clinicians should evaluate patient history and monitor key parameters. - Hepatic function: assess baseline liver enzymes and repeat periodically. - Cardiovascular risk: screen for hypertension, arrhythmia and prior events. - Seizure history: avoid in patients with prior seizures. - Drug interactions: review concomitant medications that affect CYP3A4. - Pregnancy and lactation: contraindicated in women of childbearing potential; ensure effective contraception. - Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture and light.

Darolide may interact with several medicines that influence its metabolism or transport.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce darolutamide exposure. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase exposure and toxicity. - BCRP and OATP1B3 inhibitors (e.g., cyclosporine): heightened plasma levels.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): potential alteration of INR.\n- Statins metabolised by CYP3A4 (e.g., simvastatin, atorvastatin): may require dose adjustment. - Antihypertensive agents: additive blood‑pressure effects. - Proton pump inhibitors: possible effect on absorption. - Herbal supplements: St St